atenolol / Generic mfg. - LARVOL DELTA

Introducing Allopurinol to the Medical Treatment of Marfan Syndrome: Advantages, Limitations, and Potential Extension to other Aortopathies. (PubMed, Cardiovasc Drugs Ther) - "Allopurinol is a widely used compound in medical practice for gout, and has been proven safe, economical and effective in other cardiovascular diseases. The recent approval of allopurinol as an orphan drug for the treatment of MFS by the European Medicines Agency (EMA) adds further value to its potential inclusion in standard medical therapy in the near future."

Journal • Review • Cardiovascular • Genetic Disorders • Gout • Inflammatory Arthritis • Rheumatology • FBN1

Drugs for prevention of migraine. (PubMed, Med Lett Drugs Ther) - No abstract available

Journal • CNS Disorders • Migraine • Pain

Comparative analysis of infarct-reducing properties of ß1 -, ß2 -, and ß3 -adrenergicreceptor ligands in ischemia and reperfusion of the heart. (PubMed, Pharmacology) - "β 1 -AR blockade increases cardiac tolerance to I/R in vivo. β 2 -AR blockade and β 2 - AR stimulation do not affect cardiac resistance to I/R in vivo. β 3 -AR blockade does not affect cardiac resistance to I/R in vivo."

Journal • Anesthesia • Cardiovascular • Myocardial Infarction

Drugs associated with retroperitoneal fibrosis: assessment of the 1969-2025 Food and Drug Administration (FDA) pharmacovigilance database. (PubMed, Pharmacol Rep) - "This pharmacovigilance analysis identified multiple medications, spanning different therapeutic classes, that demonstrated a disproportionate association with reports of RPF. Notably, some drugs with well-established safety profiles also emerged as potential signals, warranting increased clinical awareness. While this analysis reveals pharmacovigilance signals suggestive of drug-induced RPF, the observational nature of FAERS data limits causal inference. These findings underscore the need for further clinical research and mechanistic studies to better understand the etiopathogenic role of these agents in RPF development."

Adverse events • Journal • Fibrosis • Immunology • Inflammation • Nephrology • Renal Disease

An Analyte-Specific LC-IMS-HRMS Framework for Enhanced Identification Confidence in Target Screening of Contaminants in Complex Matrices. (PubMed, Anal Chem) - "Additionally, both differentiation based on CCS values (e.g., atenolol-practolol) and mandatory detection of predefined qualifiers (e.g., prometryn-terbutryn) decreased false positives. By incorporating the TIMS dimension and mandatory qualifiers as additional identification information, this work provides a robust framework for high-throughput environmental monitoring and human exposure assessment."

Journal

Immobilized horseradish peroxidase hybrid biocatalysts for degradation of pharmaceuticals and other emerging micropollutants. (PubMed, PLoS One) - "For example, full degradation was achieved for MBT (100%), meloxicam (99.5%) and caffeic acid (98.6%). In contrast, prometryn and MCPA showed only partial degradation, reaching 19.2% and 20%, respectively, and no degradation was observed for fluometuron and atenolol...For instance, roxithromycin degradation increased from 0.5% to 58.2% with ZnO-HRP, and for cimetidine, TiO₂-HRP improved degradation from 0.3% to 60.1% without HOBT and from 9.0% to 66.7% with HOBT...Finally, an integrated HRP enzyme and chemical oxidation remediation strategy was applied to degrade two pollutants, trimethoprim and DEET. For trimethoprim, TiO2-HRP combined with H2O2 and UV achieved approximately 30% degradation, while for DEET, both TiO2-HRP + H2O2 + UV and ZnO-HRP + H2O2 + UV resulted in around 40% degradation, thereby highlighting a novel application for these hybrid peroxidase-photocatalysts."

Journal

Efficacy and Tolerability of Atenolol vs. Propranolol in Treating Infantile Hemangiomas (EADV 2026) - No abstract available

Clinical • Vasculitis

Recurrent Cardiac Arrest in a Pediatric Patient with Hypertrophic Cardiomyopathy and a Myocardial Bridge: Player or Spectator? (PubMed, Pediatr Cardiol) - "Atenolol was started after his second SCA at age 12. After a third SCA he was transitioned to Nadolol and Mexiletine, and underwent transvenous ICD implantation due to delayed shock secondary to under-sensing on epicardial system. He had two additional episodes of SCA, for which he was started on Amiodarone and transferred to our institution for transplant evaluation in the setting of biventricular systolic dysfunction...MB can cause significant compression leading to compromised coronary flow and myocardial ischemia distinct from the intrinsic underlying cardiomyopathy in HCM. Modifiable causes should be considered in cases of recurrent SCA, as treatment may alter prognostic implications."

Journal • Cardiomyopathy • Cardiovascular • Fibrosis • Hypertrophic Cardiomyopathy • Immunology • Myocardial Ischemia • Pediatrics • Transplantation

Transcellular permeation of small molecule drugs with permeation enhancers | Poster Board #D26 (ACS-Fall 2026) - "This work focuses on two PEs, sodium caprate (C10) and salcaprozate sodium (SNAC), and their influence on membrane structure and the free energy of permeation of neutral (mannitol, atenolol, ketoprofen, decanedecaol, and mucic acid) and charged (ketoprofen, propranolol, and salicylic acid) small molecule drugs. Analyses revealed that the membrane interior becomes more hydrophilic with PEs by providing more opportunities for drug-PE and drug-water hydrogen bonding—these interactions are correlated with a decrease in the central barrier of permeation. These results will pave the way as prototypes for future work regarding peptides, to account for the size and charged group dependency, and the extent to which it influences the free energy of permeation."

Sex-differential outcomes of beta-blocker therapy after myocardial infarction with preserved ejection fraction: a propensity-matched study of 554,110 patients (ESC 2026) - "Beta-blocker recipients (metoprolol, bisoprolol, carvedilol, or atenolol within 30 days) were compared with non-recipients (no beta-blocker within 90 days). We did not find the outright harm reported in REBOOT, but the therapeutic window in women is considerably narrower. These results argue against a one-size-fits-all approach and support incorporating sex into prescribing decisions for post-MI secondary prevention."

Clinical • Atrial Fibrillation • Cardiovascular • Congestive Heart Failure • Dyslipidemia • Heart Failure • Hypertension • Hypotension • Myocardial Infarction

Anti-Resorptive Effects of Atenolol Are Associated With Altered Transcriptional Metabolic Profiles in Human Osteoclasts (ASBMR 2026) - No abstract available

Late-breaking abstract

Analysis of real water samples with AQbD microextraction using thymol-based NADES: implications of uncontrolled hypertension risk in Egypt. (PubMed, Anal Methods) - "This work developed a green analytical method for the simultaneous determination of three model antihypertensive agents from distinct classes, namely, furosemide, atenolol, and lisinopril, in water samples. A comprehensive greenness assessment using the GAPI, AGREE, BAGI, and EVG tools confirmed strong alignment with sustainable chemistry principles. By enabling multi-class extraction of antihypertensive drugs with a low-ecological-footprint NADES-based protocol, this method addresses a critical gap as no prior NADES-based method exists for these three therapeutic classes together, supporting environmental monitoring and clean water objectives."

Journal • Cardiovascular • Hypertension

Impact of chronic beta-blocker versus renin-angiotensin inhibitor use on outcomes after blunt pelvic trauma. (PubMed, Surgery) - "Prior use of β-blockers is correlated with significantly worse rates of hemorrhage, infection, and thromboembolic events after a traumatic pelvic fracture when compared with renin-angiotensin system inhibitors. This could be due to renin-angiotensin system inhibitors attenuating the post-traumatic inflammatory response system by blocking angiotensin II, which causes inflammation, oxidative stress, endothelial dysfunction, and vasoconstriction. These findings suggest that chronic cardiovascular therapy type may influence post-pelvic trauma outcomes, underscoring the need for further investigation."

Journal • Cardiovascular • Hematological Disorders • Infectious Disease • Inflammation • Musculoskeletal Diseases • Orthopedics • Pneumonia • Pulmonary Embolism • Respiratory Diseases • Septic Shock

Enalapril, Atenolol, Alendronate and DRESS Syndrome - A Case Report. (PubMed, Acta Derm Venereol) - No abstract available

Journal

Impact of atenolol on oyster hemocytes: a model for assessing pharmaceutical immunotoxicity. (PubMed, Environ Toxicol Chem) - "Furthermore, differences in response by agranulocytes and granulocytes were observed, supporting the need to evaluate hemocyte subpopulations along with the whole population. These findings suggest oyster hemocytes may be a useful tool in addressing the gap of knowledge in ecotoxicological impacts of emerging contaminants on marine organisms and can serve as a preliminary assessment of immunotoxicity of these contaminants prior to in-vivo experiments."

Journal

Black Elderberry Exposure in Apparent Idiopathic Mild Acute Pancreatitis: A Case Report. (PubMed, Cureus) - "Medication reconciliation revealed daily use of black elderberry extract along with chronic losartan, atenolol, niacin, aspirin, and latanoprost. Because occult biliary disease and medication co-exposure could not be definitively excluded, causality was conservatively classified as possible black elderberry-associated acute pancreatitis. This case reviews the importance of explicit supplement reconciliation in apparent idiopathic acute pancreatitis and the need for endoscopic ultrasound or magnetic resonance cholangiopancreatography after recovery in older adults when initial evaluation is unrevealing."

Journal • Cardiovascular • Dyslipidemia • Hepatology • Hypertension • Pain • Pancreatitis

Effect of atenolol versus ivabradine on heart rate variability in patients of schizophrenia with clozapine-induced tachycardia: a randomized controlled trial. (PubMed, Psychiatry Res) - P=N/A | "No significant between-group differences in HRV parameters were established between atenolol and ivabradine. Ivabradine could be a viable option in patients where atenolol is either contraindicated or not tolerated. Future larger multicentric studies are needed for greater generalisability."

Journal • Cardiovascular • CNS Disorders • Psychiatry • Schizophrenia

A meta-analysis of randomized controlled trials on atenolol's impact on postoperative atrial fibrillation in adults undergoing cardiac surgery. (PubMed, Medicine (Baltimore)) - "Atenolol did not demonstrate superiority over sotalol in reducing POAF (RR, 2.39; 95% CI: 1.41-4.04; P = .001) with moderate heterogeneity (I2 = 40%; P = .19). Furthermore, no significant difference was observed between atenolol and the control group (comprising propafenone, metoprolol, nebivolol, and digoxin) in the prevention of POAF (RR, 1.28; 95% CI: 0.76-2.16; P = .35) with moderate heterogeneity (I2 = 43%; P = .15). Recent studies suggest that atenolol could be a safe and effective intervention for the prevention of POAF in adult patients undergoing CS."

Clinical • Journal • Retrospective data • Atrial Fibrillation • Cardiovascular

Effects of the beta1-selective blocker atenolol on bone loss in postmenopausal women: Results of a double-blind placebo-controlled randomized trial (ASBMR 2026) - No abstract available

Clinical • Osteoporosis

Pharmaceutical cocktails in aquatic ecosystems: unveiling the hidden ecotoxicological threats to Microcystis aeruginosa. (PubMed, Environ Geochem Health) - "This study evaluates the individual and combined effects of four commonly detected pharmaceuticals in aquatic environments: acetaminophen (APAP), atenolol (ATN), carbamazepine (CBZ), and diazepam (DZP), using the model cyanobacterium Microcystis aeruginosa over a 25-day exposure period at environmentally relevant concentrations (0.01-545 µg/L). Overall, the multi-biomarker responses indicate that pharmaceutical mixtures overwhelm cellular defenses, inducing amplified stress responses even at environmentally realistic concentrations. These findings highlight the urgent need to incorporate mixture toxicity into risk assessment frameworks."

Journal

A Comprehensive Review of the Current Systemic Medical Treatment Landscape for Vascular Malformations. (PubMed, Pediatr Dermatol) - "Options for hemangioma treatment include systemic beta-blockers such as propranolol, atenolol, and nadolol, and the topical beta-blocker timolol...Recent pharmacological and technological advances in the medical management of vascular anomalies have decreased the need for surgery in many patients while also leading to improved outcomes and quality of life. This review will guide the dermatologist through the current medical treatment landscape for vascular malformations."

Journal • Review • Dermatology • Oncology • Pediatrics

Efficacy and safety of interventions for infantile hemangioma compared with oral propranolol: an updated systematic review and bayesian network meta-analysis. (PubMed, Eur J Pediatr) - " By anchoring all comparisons to oral propranolol and integrating CINeMA certainty assessments with inconsistency testing, these findings are consistent with the continued role of oral propranolol as the reference systemic treatment for infantile hemangioma. For patients intolerant to propranolol, atenolol may represent a reasonable alternative."

Clinical • Journal • Retrospective data • Review

Genetic Bone Diseases: A Scoping Review of Pathology, Symptoms, Diagnosis, Treatment, and New Horizons. (PubMed, Adv Genet (Hoboken)) - "These treatments include: fresolimumab for osteogenesis imperfecta, small interfering ribonucleic acid (RNA) therapy for Osteopetrosis, denosumab for Paget's disease of bone, vosoritide/recifercept/infigratinib for achondroplasia, mesenchymal stem cell therapy for craniosynostosis, and combination losartan and atenolol therapy for Marfan syndrome. These treatments are generally more recently acknowledged in literature and are either actively undergoing research or require further research to determine their efficacy."

Journal • Review • Genetic Disorders • Orthopedics • Rare Diseases

Beta-Blockers and Exercise Performance in Children with Long QT Syndrome. (PubMed, JACC Clin Electrophysiol) - "In children with LQTS, we did not observe any relationship between higher nadolol doses and objective measures of effort (peak RER) or cardiopulmonary fitness (peak Vo2), despite a linear dose-response between nadolol dose and %PHR. These results suggest that treatment with nadolol for LQTS does not affect most patients' peak exercise performance. These data were validated in patients from an earlier era who had been prescribed atenolol."

Journal • Cardiovascular • Pediatrics

Metagenomic insights into microbial drivers of organic micropollutant removal in wastewater-impacted riverbank filtration. (PubMed, Water Res) - "Sediment preferentially attenuated hydrophilic or charged compounds, including lidocaine, amantadine, and sotalol, whereas soil contributed more strongly to the attenuation of naproxen, atenolol, and losartan. These findings indicate that sediment and soil develop complementary microbial functional potentials that may support compound-specific OMP attenuation. This study provides a mechanistic basis for optimizing sediment-soil configurations in wastewater-impacted RBF systems and for improving nature-based barriers against diverse OMP mixtures."

Journal